Inclusion Criteria:

• Age ≥ 18 years of age.
• ECOG Performance Status of ≤ 2.
• Measurable tumor by direct visualization requiring surgical resection in the OR.
• Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, and sarcoma. Tumors may be primary or metastatic to solid or hollow intra-abdominal organs.
• Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent.
• Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein.

Exclusion Criteria

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations.
• Renal dysfunction as defined as a GFR < 45.
• Liver dysfunction as defined by Child-Pugh score > 5, or LFT's 1.5x above normal range.
• Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein.
• Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test.
• Unwilling or unable to follow protocol requirements.
• Any condition which in the Investigators' opinion deems the patient unsuitable (e.g., abnormal EKG, including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test).
• Any condition that excludes surgery as the standard of care (e.g. high disease burden where alternative treatments like systemic chemotherapy would be preferred).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 6/22/23. Questions regarding updates should be directed to the study team contact.